Verseon Corporation (“Verseon” or the “Company”)
Additional Listing and Total Voting Rights
Verseon, a technology-based pharmaceutical company, announces that application has been made for 1,875 new Common Shares of par value $0.001 each (the “Common Shares”) to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units (the "Issuance"). The Issuance is in connection with the Verseon Corporation 2015 Equity Incentive Plan and pursuant to the regularly scheduled vesting of previously granted restricted stock units.
The 1,875 new Common Shares will rank pari passu with the Company's existing Common Shares. Admission to trading on AIM is expected to take place on 21 November 2016 ("Admission").
Total Voting Rights
Following Admission, the issued share capital of the Company will consist of 151,414,659 Common Shares. The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 151,414,659. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
|Arthur Shmurun / Amy Thai||+1 (510) 225 9000|
|Cenkos (NOMAD and Joint Broker)|
|Mark Connelly / Steve Cox||+44 (0) 20 7397 8900|
|Cantor Fitzgerald Europe (Joint Broker)|
|Marc Milmo / Phil Davies / Callum Butterfield||+44 (0) 20 7894 7000|
|Mirabaud Securities LLP (Joint Broker)|
|Peter Krens||+44 (0) 20 7321 2508|
|Buchanan Communications Ltd (PR Advisors)|
|Henry Harrison-Topham / Sophie Cowles||+44 (0) 20 7466 5000|